InvestorsHub Logo
Followers 16
Posts 395
Boards Moderated 0
Alias Born 06/07/2009

Re: md1225 post# 216794

Friday, 04/24/2015 4:13:28 PM

Friday, April 24, 2015 4:13:28 PM

Post# of 345746

I'm praying the next PR is bavituximab/Opdivo frontline lung cancer.



Note that the competition already paring with Opdivo.
From Celldex's AACR poster...

A Phase 1/2 dose escalation and cohort expansion study of varlilumab and Anti-PD-1 (nivolumab) in refractory solid tumors- Currently enrolling



Varlilumab appears to be a serious threat. If the 9/12 event hadn't occurred, we could be doing that today.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News